众生药业：子公司获得聚乙烯醇化学原料药上市申请批准通知书

Core Viewpoint - The announcement highlights that Zhongsheng Pharmaceutical's subsidiary, Guangdong Xianqiang Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing authorization of the raw material drug Polyvinyl Alcohol, which is used in eye drops to alleviate symptoms of dryness and irritation [1] Company Summary - Zhongsheng Pharmaceutical's subsidiary has been granted a marketing authorization for Polyvinyl Alcohol, a high molecular polymer with hydrophilic and film-forming properties [1] - The approved product, Polyvinyl Alcohol eye drops, serves as a lubricant to prevent or treat symptoms such as dryness, foreign body sensation, and eye fatigue [1] Industry Summary - Polyvinyl Alcohol is recognized for its application in ophthalmic solutions, providing lubrication and protection to the eye surface [1] - The approval of this product indicates a potential growth opportunity in the ophthalmic market, particularly for treatments addressing dry eye symptoms [1]